Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHA-PQP MDA for Malaria Elimination in Mozambique
NCT02914145Completed
- Sponsor
- Manhiça Health Research Centre
- Start
- Nov 2015
- Primary completion
- Dec 2017
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
Open-label, single-arm trial of dihydroartemisinin + piperaquine in malaria, sponsored by Manhiça Health Research Centre. Primary endpoints: Decrease in Parasite prevalence according to RDT at 6 months, Decrease in Parasite prevalence according to PCR at 6 months and 1 more. Started Nov 2015; status: completed.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02914145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914145.